Role of Peripheral Vision in Scene Perception (PERISCE) (PERISCE)

September 13, 2022 updated by: University Hospital, Grenoble

Role of Peripheral Vision in Scene Perception

Despite its low spatial resolution, peripheral vision is very useful for rapidly categorizing a visual scene. Low spatial frequencies of a visual stimulus available in peripheral vision would allow a coarse categorization of the scene and objects (deciding, for example, whether it is an urban or natural landscape). This first representation would then trigger predictive mechanisms which would subsequently guide a more detailed visual analysis in central vision. The psychophysical studies that the investigators have already conducted in this scientific context has been carried out under normal vision conditions. The objective of this project is to study the influence of peripheral vision on central vision with an original approach: What are the consequences of a loss of peripheral vision on the processing performed in central vision? The project will concern patients with glaucoma. This ophthalmic pathology particularly affects the peripheral retina and thus represents a good pathological cognitive model of a visual recognition system in which peripheral vision is less important. The investigators will conduct psychophysical studies with glaucomatous patients and healthy volunteers with normal vision. All participants will be required to perform a short experiment on a computer (15 minutes) where they will look at different photographs of scenes of different luminance and spatial frequencies. Participants will have to perform various tasks on these images using the keys on the keyboard.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Anticipated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

POAG patients and age-matched normally sighted controls

Description

Inclusion Criteria:

For patients :

  • between 18 and 80 years old
  • stable bilateral primary open angle glaucoma (POAG)
  • visual acuity > 5/10 for distant vision for the eye tested
  • peripheral visual field defect on the eye tested measured through a Humphrey Visual Field Analyzer

For healthy volunteers :

  • between 18 and 80 years old
  • visual acuity > 5/10
  • absence of ophthalmologic disease other than Glaucoma (age-related macular degeneration, cataract except for uncomplicated cataract surgery, amblyopia, optic neuropathy, diabetic retinopathy …)

Exclusion Criteria:

  • ophthalmologic disease other than Glaucoma (age-related macular degeneration, cataract except for uncomplicated cataract surgery, amblyopia, optic neuropathy, diabetic retinopathy …)
  • treated with medication that might compromise sustained attention (benzodiazepine, narcoleptics)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Primary open-angle glaucoma (POAG) group
Behavioral: Psychophysical evaluation
All participants will be required to perform a short experiment on a computer (15 minutes) where they will look at different photographs of scenes of different luminance and spatial frequencies. They will have to perform various tasks on these images using the keys on the keyboard.
Age-matched normally sighted control group
Behavioral: Psychophysical evaluation
All participants will be required to perform a short experiment on a computer (15 minutes) where they will look at different photographs of scenes of different luminance and spatial frequencies. They will have to perform various tasks on these images using the keys on the keyboard.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Psychophysical measure : Percentage of correct response
Time Frame: Through study completion of 45 months
Measure calculated by the comparison between the expected response and the response provided by the participant for each trial of the experiment
Through study completion of 45 months
Psychophysical measure : Mean reaction time in milliseconds
Time Frame: Through study completion of 45 months
Measure calculated by averaging the time in milliseconds taken by the participant to provide the response for each trial of the experiment
Through study completion of 45 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University Hospital, Grenoble

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 1, 2022

Primary Completion (Anticipated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 1, 2026

Study Completion (Anticipated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 23, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 13, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 14, 2022

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 14, 2022

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 13, 2022

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2021-A01986-35

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

Anonymized individual participant data will be share in the context of publications through the Open Science Framework, a tool that promotes open, centralized workflows.

IPD Sharing Time Frame

Data will become available after publications with no limit time

IPD Sharing Access Criteria

Link to the Open Science Framework

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings